CSIMarket Company Name, Ticker, Customers, else..
 
Enzon Pharmaceuticals inc   (ENZN)
Other Ticker:  
 
 
Price: $0.1500 $0.01 7.066%
Day's High: $0.1524 Week Perf: 0.07 %
Day's Low: $ 0.14 30 Day Perf: -20.17 %
Volume (M): 193 52 Wk High: $ 0.24
Volume (M$): $ 29 52 Wk Avg: $0.12
Open: $0.15 52 Wk Low: $0.06



 Market Capitalization (Millions $) 11
 Shares Outstanding (Millions) 74
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) 2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Enzon Pharmaceuticals Inc
Enzon Pharmaceuticals Inc is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapies for the treatment of cancer and other serious diseases. The company was founded in 1981 and is headquartered in Piscataway, New Jersey.

Enzon Pharmaceuticals has a unique approach to drug development, using a proprietary technology platform called PEGylation. PEGylation involves attaching polyethylene glycol (PEG) chains to therapeutic proteins or drug molecules, which can enhance their efficacy and prolong their circulation time in the body.

The company's product portfolio includes several PEGylated drugs that have been approved by regulatory authorities and are marketed in the United States and other countries. These drugs target a range of diseases, including breast cancer, lung cancer, and multiple myeloma.

In addition to its commercial products, Enzon Pharmaceuticals also has a robust pipeline of drug candidates in various stages of development. The company actively engages in strategic collaborations and partnerships to leverage its technology platform and expand its product portfolio.

Enzon Pharmaceuticals is committed to advancing patient care and improving outcomes. Through its innovative therapies and ongoing research efforts, the company strives to make a meaningful impact in the field of biopharmaceuticals.


   Company Address: 20 Commerce Drive (Suite 135) Cranford 7016 NJ
   Company Phone Number: 980-4500   Stock Exchange / Ticker: ENZN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN      % 
BIIB      % 
CHRS      % 
EXEL      % 
GILD      % 
HALO      % 
• View Complete Report
   



Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals Inc Boasts Impressive 44.743% Revenue Surge in Q1 2024 Earnings Report



Enzon Pharmaceuticals Inc, a leading player in the Biotechnology & Pharmaceuticals industry, recently reported its first quarter 2024 earnings. Despite the industry facing challenges, Enzon's financial figures paint a bleak picture. With zero earnings per share and a marginal increase in revenue, the company's performance raises concerns about its future prospects. This article delves into the factors contributing to Enzon's poor performance while comparing it to the broader industry landscape.
Lackluster Earnings Performance
Enzon Pharmaceuticals Inc declared a stagnant earnings figure of $0.00 per share for the first quarter of 2024. This result is in stark contrast to the same reporting period a year ago, as well as the prior quarter. Despite overall positive sentiment within the Biotechnology & Pharmaceuticals sector, Enzon failed to capitalize on the industry's growth potential.
Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals Rides High with Impressive Revenue Growth Despite Break-even Earnings

Enzon Pharmaceuticals Inc (Enzon) shares have experienced a substantial increase of 18.29% in the past five trading days. This surge in share price is a positive development for the biotechnology and pharmaceutical company, albeit with a cautionary note as the shares are trading only 36.2% above their 52-week low.
In the recent financial report for the fiscal year ending on December 31, 2023, Enzon announced break-even earnings per share (EPS) of $0.00, compared to $0.01 in the same period the previous year. Despite this drop in EPS, there was significant growth in revenue, with an increase of 2357.692% during the corresponding period.
Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals Inc Generates Impressive Revenue of $0.622 Million in Q3 2023

Enzon Pharmaceuticals Inc is a pharmaceutical company that recently reported its financial results for the period ending September 30, 2023. The company announced a revenue of $0.622 million, which represents an improvement compared to the previous year's reporting period. Additionally, Enzon Pharmaceuticals Inc achieved a net earnings of $0.321 million, indicating a significant improvement from a net deficit of $-0.015 million in the same period last year.
These positive financial results reflect the company's ability to generate revenue and increase profitability. Enzon Pharmaceuticals Inc's management should be commended for their efforts in turning around the financial performance of the company.
Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals Faces Uncertain Future with Alarming Plunge to Just $0.553 Million Revenue in Recent Fiscal Period

Enzon Pharmaceuticals Inc. (ENZN) is facing a challenging future as the company reported lower revenue and net earnings in the April to June 2023 fiscal period. The company posted only $0.553 million in revenue, a disappointing figure that indicates a lack of growth and potential for profitability.
In the same reporting period a year ago, Enzon Pharmaceuticals Inc. suffered a net deficit of $-0.213 million, highlighting the company's struggle to generate positive earnings. Although there was an improvement to a net earnings of $0.183 million in the current fiscal span, this figure remains significantly lower, indicating that the company has a long way to go before achieving consistent profitability.
Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals Inc Skyrockets Revenue to $0.447 Million, Surpassing Last Year's Performance

Enzon Pharmaceuticals Inc, a biotechnology and pharmaceuticals company, has just released its financial report for the first quarter of 2023. The report shows that the company generated revenue of $0.447 million during the quarter, which represents a significant increase in revenue compared to the same reporting period a year ago.
Furthermore, the report also shows that Enzon Pharmaceuticals Inc achieved earnings of $0.197 million in the financial first quarter of 2023, a significant improvement from the net loss of $-0.291 million in the comparable financial reporting period from a year ago. This improvement in the company's performance is a result of their efforts to improve operational efficiency and optimize their product offerings.






Enzon Pharmaceuticals Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com